



Semintra[®]—designed with cats and owners in mind


The first and only liquid solution for the management of chronic kidney disease* and hypertension in cats



*Reduction of proteinuria associated with chronic kidney disease in cats.



Contents



CHRONIC KIDNEY DISEASE AND HYPERTENSION

HEALTH CHECK PROGRAMME

MANAGING CKD AND HT WITH SEMINTRA

PROVEN BENEFITS

MODE OF ACTION


SAFETY

QUALITY OF LIFE AND COMPLIANCE

SUMMARY

Semintra
THE SOLUTION

CKD and HT are very common in cats and often occur together




OF CATS WITH CKD ARE HYPERTENSIVE²



OF HYPERTENSIVE CATS HAVE CKD²


The 4 stages of feline CKD progression



At the later stages of the disease, clinical signs increase and life expectancy decreases⁵⁻⁷

*Median life expectancy at diagnosis based on IRIS stage following rehydration with fluid therapy.

Risk categories for HT⁸



As HT increases, the risk of damage to the kidneys, heart, brain and eyes increases

CKD and HT: Early diagnosis and treatment are vital



CKD

Clinical signs of feline CKD only appear late in disease—by when most kidney function has been irreversibly lost⁹

HT

Clinical signs of HT only occur once there is significant damage to the kidneys, heart, brain and eyes^{8,10}



Regular screening for CKD and HT are important so you can detect and manage disease early

Introduce a health check programme for CKD



International guidelines recommend regular clinic assessment and screening of ageing cats over 7 years of age for chronic diseases^{1,11,12}

EMPOWER CLINIC
SUPPORT STAFF

1


SCREENING
AND REGULAR
ASSESSMENT

2

TREAT AND
FOLLOW UP

3

1 Empower clinic support staff



Gather contact details of all owners with **cats over 7 years of age**




Invite cats and owners for screening visits/health visits and explain:

- Outward signs of CKD are not seen until very late
- CKD and HT are linked. Both impact the quality of life and lifespan of affected cats and are more prevalent as cats age
- Early disease detection is only possible via clinic assessment



Engage with cat owners proactively to maximise overall patient care and clinic potential

② Screening and regular assessment



Guidelines recommend the following procedures for cats over 7 years^{1,11}:




Physical examination

- Record body weight and hydration




Urine analysis

- USG
- UP:C



Blood sample

- PCV, total protein, SDMA, urea and creatinine



Perform further tests

- Blood pressure
- Renal ultrasound if available



Advise 6- to 12-monthly screening for patients with no evidence of CKD or HT

③ Treat and follow up



Start patients with evidence of CKD* and/or HT on Semintra



Reassure daily treatment compliance provides the best health benefits for their cat and maintains quality of life




Maximise patient outcomes via regular clinic visits



Semintra is central in the management of CKD and HT

Semintra is central to the management of concurrent CKD and HT⁹



SEMINTRA, A RENAL DIET/SUPPLEMENT AND INCREASED FLUID INTAKE PROVIDE **HOLISTIC MANAGEMENT FOR CKD AND HT**

*From studies in humans and rodents.

Managing CKD and/or HT with Semintra



Use Semintra when prescribing a renal diet or if there is any of the following:



Clinical signs of **CKD**, such as polyuria (PU), polydipsia (PD) and weight loss^{1,6}



Elevated **SDMA** with high, normal or elevated creatinine and a urine specific gravity (**USG**) <1.035 ^{1,7}



Urine protein to creatinine ratio (**UP:C**) ≥ 0.2 ^{1,7}



Raised **blood pressure** ≥ 160 mmHg on two occasions or clear evidence of hypertensive damage to kidneys, heart, brain or eyes^{8,10}

Semintra effectively blocks the vicious cycle of CKD and HT



Kidney damage causes chronic RAAS activation, glomerular HT and proteinuria¹




Semintra modulates the RAAS to protect the kidneys, reduces proteinuria AND reduces blood pressure¹³



Break the vicious cycle in proteinuric CKD and HT with Semintra

Sustained reduction of proteinuria versus benazepril




Semintra provided a sustained reduction of proteinuria from below baseline, whereas benazepril did not¹⁴


Prompt and sustained reduction in systolic blood pressure



- Sustained efficacy over 120 days of study duration^{15,16}
- Proven in large multicentre clinical trials^{15,16}



A targeted mode of action to promote unique benefits




As an **ARB**, **Semintra (telmisartan)** has a unique, targeted MOA that:

- Harnesses the protective benefits of the cat's RAAS
- Promotes protection of the kidneys and other vital organs while optimising blood pressure




Chronic RAAS activation is central to the vicious cycle of CKD and development of HT





*Glomerular damage and tissue inflammation leading to a loss of functioning nephrons, overload of remaining nephrons and fibrosis.


Semintra breaks the vicious cycle of CKD and reduces blood pressure



Semintra's targeted MOA harnesses the protective benefits of the RAAS




Semintra harnesses the protective benefits of the RAAS, whereas ACEi and amlodipine do not



RAAS signalling occurs through AT_2 only, harnessing the protective benefits of the RAAS



RAAS signalling is reduced through both AT_1 and AT_2 —both harmful effects and protective benefits are partially reduced and **ACE escape** may occur



Amlodipine does not affect the RAAS, which remains chronically activated

Semintra has an excellent safety profile



Safe for **long-term administration**¹³



Safe for **concomitant use with renal diets and phosphate binders** at both the reno-protective and anti-HT doses¹³




Safe for **use with amlodipine** at the reno-protective dose^{13,*}

Semintra improves quality of life



Cat owners reported maintenance or improvement of¹⁷:



ADMINISTER SEMINTRA EARLY TO MAXIMISE KIDNEY HEALTH AND REDUCED BLOOD PRESSURE TO PROMOTE AN IMPROVED QUALITY OF LIFE

*Appetite was perceived to be maintained in 51% of cats and improved in 40% of cats, and activity levels were perceived to be maintained in 51% of cats and improved in 41% of cats.

Semintra is an ideal solution for cats and cat owners



- Well accepted liquid formulation
- Easy to draw up and administer directly into the mouth or over a small amount of food
- Drives cat owner compliance and improves quality of life¹⁷

THE STATISTICS:



PREFERRED
LIQUID
MEDICATION
TO TABLETS¹⁷



EASILY
MEDICATED
THEIR CAT¹⁷



Semintra is easy to dose and administer



1x

Easy-to-give, once-daily oral solution, administered directly into the mouth or over a small amount of food




Calibrated syringe provided for precise and accurate dosing

CKD+HT

Two concentrations (4 and 10 mg/ml) available for optimal disease management

Semintra
THE SOLUTION

Semintra—the unique solution for feline CKD* and HT



Disease

- **CKD and HT are very common**, often interacting, silent diseases
- **Both diseases are triggered by chronic RAAS activation** and detract from the quality of life of both cat and owner

Proven and protective


- Semintra has **strong clinical evidence** of safety and efficacy
- Semintra's **targeted mode of action works with the RAAS**— harnessing its **protective benefits**, not blocking or bypassing it, therefore **treating both CKD and HT in one solution**

Easy and well accepted

Semintra promotes better compliance and quality of life as it:

- Is **easy to give** and well accepted by >90% of cats¹⁸
- Makes **individualised accurate dosing** simple
- Is **easily combined** with renal diets and supplements

References



1. Sparkes AH, Caney S, Chalhoub S, et al. ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease. *J Feline Med Surg.* 2016;18:219–239.
2. Bijmans ES, Jepson RE, Chang YM, Syme HM, Elliott J. Changes in systolic blood pressure over time in healthy cats and cats with chronic kidney disease. *J Vet Intern Med.* 2015;29:855–861.
3. Bodey AR, Sansom J. Epidemiological study of blood pressure in domestic cats. *J Small Anim Pract.* 1998;39:567–573.
4. Jepson RE. Feline systemic hypertension: classification and pathogenesis. *J Feline Med Surg.* 2011;13:25–34.
5. Boyd LM, Langston C, Thompson K, Zivin K, Imanishi M. Survival in cats with naturally occurring chronic kidney disease (2000-2002). *J Vet Intern Med.* 2008;22:1111–1117.
6. Polzin DJ. Chronic kidney disease. In: Ettinger SJ, Feldman EC, Côté, E, eds. *Veterinary Internal Medicine.* 8th edition. St. Louis, MO: Elsevier; 2017:1938–1959.
7. IRIS Staging of CKD. International Renal Interest Society website. Available at: http://www.iriskidney.com/pdf/IRIS_Staging_of_CKD_modified_2019.pdf. Accessed February 28, 2022.
8. Acierno MJ, Brown S, Coleman AE, et al. ACVIM consensus statement: guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. *J Vet Intern Med.* 2018;32:1803–1822.
9. Taylor S, Sparkes AH. Feline CKD: new horizons - where do we go from here? *J Feline Med Surg.* 2013;15 Suppl 1:45–52.
10. Taylor SS, Sparkes AH, Briscoe K, et al. ISFM consensus guidelines on the diagnosis and management of hypertension in cats. *J Feline Med Surg.* 2017;19:288–303.
11. Ray M, Carney HC, Boynton B, et al. 2021 AAFP feline senior care guidelines. *J Feline Med Surg.* 2021;23:613–638.
12. Quimby J, Gowland S, Carney HC, DePorter T, Plummer P, Westropp J. 2021 AAHA/AAFP feline life stage guidelines. *J Feline Med Surg.* 2021;23:211–233.
13. Semintra Summary of Product Characteristics (SPC). European Medicines Agency website. Available at: https://www.ema.europa.eu/en/documents/product-information/semintra-eparproduct-information_en.pdf. Accessed February 28, 2022.
14. Sent U, Gössl R, Elliott J, Syme HM, Zimmering T. Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease. *J Vet Intern Med.* 2015;29:1479–1487. Erratum published in *J Vet Intern Med.* 2016;30:689.
15. Glaus TM, Elliott J, Herberich E, Zimmering T, Albrecht B. Efficacy of long-term oral telmisartan treatment in cats with hypertension: results of a prospective European clinical trial. *J Vet Intern Med.* 2019;33:413–422.
16. Coleman AE, Brown SA, Traas AM, Bryson L, Zimmering T, Zimmerman A. Safety and efficacy of orally administered telmisartan for the treatment of systemic hypertension in cats: Results of a double-blind, placebo-controlled, randomized clinical trial. *J Vet Intern Med.* 2019;33:478–488.
17. Zimmering TM, Verena Heck E, Adams J. Effect of Semintra® and owner observations on quality of life effects in cats with chronic kidney disease – update on owner feedback (“EASY Programme”). Proceedings of the FECAVA EuroCongress; 15–17 October 2015; Barcelona, Spain.
18. Data on file. Boehringer Ingelheim Animal Health.

Semintra® (telmisartan) Semintra 4 mg/ml and 10 mg/ml oral solution for cats. Prescription medicine. QC09CA07. Indication: 4 mg/ml: Reduction of proteinuria in chronic kidney disease (CKD) in cats. 10 mg/ml: Treatment of systemic hypertension in cats. Contraindications: The safety of Semintra has not been established for cats in breeding, pregnant or lactating cats. Do not use during pregnancy or lactation. Do not use in case of hypersensitivity to the active substance or to any of the excipients. This text is based on the summary of product characteristics dated 2018-12-07. For more information see www.fass.se. For prices: See www.apoteket.se. Boehringer Ingelheim Animal Health Nordics A / S, Box 467, 201 24 Malmö, tel. 040 23 34 00, fax 040 97 27 50, www.vetportal.se